Literature DB >> 21941366

Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays.

M Ciccone1, C Agostinelli, G M Rigolin, P P Piccaluga, F Cavazzini, S Righi, M T Sista, O Sofritti, L Rizzotto, E Sabattini, G Fioritoni, S Falorio, C Stelitano, A Olivieri, I Attolico, M Brugiatelli, P L Zinzani, E Saccenti, D Capello, M Negrini, A Cuneo, S Pileri.   

Abstract

To better define the significance of proliferation centers (PCs), the morphological hallmark of chronic lymphocytic leukemia (CLL), lymph node biopsies taken from 183 patients were submitted to histopathologic and fluorescence in situ hybridization (FISH) studies using a 5-probe panel on tissue microarrays. Seventy-five cases (40.9%) with confluent PCs were classified as 'PCs-rich' and 108 cases (59.1%) with scattered PCs were classified as 'typical'. Complete FISH data were obtained in 101 cases (55.1%), 79 of which (78.2%) displayed at least one chromosomal aberration. The incidence of each aberration was: 13q- 36,7%, 14q32 translocations 30.8%, 11q- 24.7%, trisomy 12 19.5% and 17p- 15.6%. Five cases showed extra copies of the 14q32 region. The 'PCs-rich' group was associated with 17p-, 14q32/IgH translocation, +12, Ki-67>30%. The median survival from the time of tissue biopsy for PCs-rich and typical groups was 11 and 64 months, respectively (P=0.00001). The PCs-rich pattern was the only predictive factor of an inferior survival at multivariate analysis (P=0.022). These findings establish an association between cytogenetic profile and the amount of PC in CLL, and show that this histopathologic characteristic is of value for risk assessment in patients with clinically significant adenopathy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21941366     DOI: 10.1038/leu.2011.247

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

Review 1.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

2.  Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway.

Authors:  P P Piccaluga; M Rossi; C Agostinelli; F Ricci; A Gazzola; S Righi; F Fuligni; M A Laginestra; M Mancini; M R Sapienza; A De Renzo; P L Tazzari; D Gibellini; P Went; F Alviano; P L Zinzani; G P Bagnara; G Inghirami; C Tripodo; S A Pileri
Journal:  Leukemia       Date:  2014-01-31       Impact factor: 11.528

3.  Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.

Authors:  F R Mauro; S Chauvie; F Paoloni; A Biggi; G Cimino; A Rago; M Gentile; F Morabito; M Coscia; M Bellò; G M Sacchetti; D Rossi; L Laurenti; F Autore; M Campanelli; F Trastulli; E Nicolai; M Riminucci; G Gaidano; A Guarini; A Gallamini; R Foà
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

4.  Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia.

Authors:  Siba El Hussein; Pingjun Chen; L Jeffrey Medeiros; John D Hazle; Jia Wu; Joseph D Khoury
Journal:  Mod Pathol       Date:  2022-02-07       Impact factor: 8.209

5.  Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Michael J Conte; Deborah A Bowen; Gregory A Wiseman; Kari G Rabe; Susan L Slager; Susan M Schwager; Timothy G Call; David S Viswanatha; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 6.  Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.

Authors:  Ryan C Lynch; Dita Gratzinger; Ranjana H Advani
Journal:  Curr Treat Options Oncol       Date:  2017-07

7.  The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia.

Authors:  Phuong-Hien Nguyen; Tamina Seeger-Nukpezah; Lisa Rusyn; Sebastian Reinartz; Anastasia Nikiforov; Nelly Mikhael; Alexander Vom Stein; Viktoria Kohlhas; Johannes Bloehdorn; Stephan Stilgenbauer; Philipp Lohneis; Reinhard Buettner; Sandra Robrecht; Kirsten Fischer; Christian Pallasch; Michael Hallek
Journal:  Leukemia       Date:  2022-05-06       Impact factor: 12.883

8.  CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.

Authors:  Sylvia Ganghammer; Evelyn Hutterer; Elisabeth Hinterseer; Gabriele Brachtl; Daniela Asslaber; Peter William Krenn; Tamara Girbl; Petra Berghammer; Roland Geisberger; Alexander Egle; Antonella Zucchetto; Anna Kruschinski; Valter Gattei; Alexandre Chigaev; Richard Greil; Tanja Nicole Hartmann
Journal:  Oncotarget       Date:  2015-05-20

9.  Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia.

Authors:  Maura Rossi; Fabio Fuligni; Maria Ciccone; Claudio Agostinelli; Simona Righi; Marco Luciani; Maria Antonella Laginestra; Gian Matteo Rigolin; Maria Rosaria Sapienza; Anna Gazzola; Claudia Mannu; Antonio Cuneo; Stefano Pileri; Pier Paolo Piccaluga
Journal:  Biomed Res Int       Date:  2013-12-12       Impact factor: 3.411

10.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.